2026-09-14T21:43:27Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1540432026-06-20T10:21:14Zcom_10366_4019com_10366_3947com_10366_3946com_10366_3823col_10366_4020

Chamorro Fernández, Antonio Javier Marcos Martín, Miguel Mirón Canelo, José Antonio Pastor Encinas, Isabel González Sarmiento, Rogelio Laso Guzmán, Francisco Javier 2024-01-08T12:36:54Z 2024-01-08T12:36:54Z 2012 Chamorro, A. J., Marcos, M., Mirón‐Canelo, J. A., Pastor, I., González‐Sarmiento, R., & Laso, F. J. (2012). Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis. Addiction biology, 17(3), 505-512. https://doi.org/10.1111/j.1369-1600.2012.00442.x 1355-6215 http://hdl.handle.net/10366/154043 10.1111/j.1369-1600.2012.00442.x 1369-1600 [EN]Previous studies have suggested that the effect of naltrexone in patients with alcohol dependence may be moderated by genetic factors. In particular, the possession of the G allele of the A118G polymorphism of the m-opioid receptor gene (OPRM1) has been associated with a better response to naltrexone, although controversial results have been reported. The aim of this paper is to combine previous findings by means of a systematic review and a meta-analysis. We retrieved studies on the relationship between A118G polymorphism in OPRM1 gene and response to treatment with naltrexone in patients with alcohol dependence by means of electronic database search. A meta-analysis was conducted using a random-effects model. Calculations of odds ratio (OR) and their confidence intervals (CI) and tests for heterogeneity of the results have been performed. Six previous studies have analyzed the role of A118G polymorphism in response to naltrexone for alcohol dependence. After meta-analysis, we found that naltrexone-treated patients carrying the G allele had lower relapse rates than those who were homozygous for the A allele (OR: 2.02, 95% CI 1.26–3.22; P = 0.003). There were no differences in abstinence rates. Our results support the fact that the G allele of A118G polymorphism of OPRM1 moderates the effect of naltrexone in patients with alcohol dependence. This genetic marker may therefore identify a subgroup of individuals more likely to respond to this treatment. eng Wiley Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Alcoholism Drug therapy Genetics Meta-analysis Naltrexone Therapeutic use Pharmacogenetics Opioid mu receptors Systematic review Pharmacogenetics Receptors, Opioid, mu Genetics Meta-Analysis Alcoholism Naltrexone Therapeutic Uses Drug Therapy alcoholismo farmacogenética naltrexona usos terapéuticos metanálisis genética farmacoterapia receptores opioides mu Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://doi.org/10.1111/j.1369-1600.2012.00442.x Addiction Biology 17 3 505 512